Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

LEO Pharma is expanding upon its ambitions in the United States (U.S.) as the FDA has accepted for filing the company’s New Drug Application (NDA) for delgocitinib cream, an investigational innovative ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

San Jose, CA, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded the Seal of ...

JOHNSON CITY, Tenn., March 27, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a fully integrated global skincare company, is excited to announce the launch of Sarna ® Eczema Relief Skin ...

Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less-than-expected benefit in a late-stage trial.After 24 weeks of treatment, ...

SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a blockbuster drug Sanofi codeveloped with Regeneron ...

CHICAGO (WLS) -- Eczema sufferers not only face severe skin problems - a new study by Northwestern University researchers now links the condition to bone fractures and other injuries. Between seven ...